- Home
- FWONA vs UTHR Comparison
FWONA vs UTHR Comparison
Compare FWONA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWONA | UTHR |
|---|---|---|
| Founded | 1950 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 25.1B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | FWONA | UTHR |
|---|---|---|
| Price | $82.85 | $582.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $101.75 | ★ $567.57 |
| AVG Volume (30 Days) | 145.8K | ★ 549.3K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $24.56 | $7.08 |
| Revenue Next Year | $5.71 | $14.32 |
| P/E Ratio | $97.75 | ★ $20.74 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $72.73 | $272.18 |
| 52 Week High | $99.49 | $607.89 |
Technical Indicators
Market Signals| Indicator | FWONA | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 61.62 |
| Support Level | $75.29 | $464.92 |
| Resistance Level | $85.60 | $607.89 |
| Average True Range (ATR) | 1.92 | 17.00 |
| MACD | 0.72 | -0.08 |
| Stochastic Oscillator | 87.74 | 67.37 |
Price Performance
Historical ComparisonAbout FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.